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In Japan, there is as yet no report on growth retardation in children with IBD. We therefore investigated the cause of growth
retardation in Japanese children with IBD. We investigated the height, body weight, serum levels of albumin, IGF-I, CRP, and
cytokines, and the amount of corticosteroid administered in children with Crohn’s disease (CD, n = 15) and ulcerative colitis
(UC, n = 18). Our results suggest that growth retardation is already present before the initial visit in children with CD, and
chronic inﬂammation may be responsible this growth disturbance. Moreover, the amount of PSL used may contribute to growth
retardation by decreasing the serum levels of IGF-I in children with IBD.
1.Introduction
Inﬂammatoryboweldisease(IBD),includingCrohn’sdisease
(CD) and ulcerative colitis (UC), is a noninvasive chronic
inﬂammatory digestive tract disorder. Recently, there has
beenanincreaseinthenumberofchildrenaﬀectedwithIBD,
as well as a tendency to aﬀect younger patients, as described
in Japanese pediatric reports [1]. Although the cause of IBD
remains incompletely understood, this disorder is thought
to be caused by the intricate involvement of immunological
abnormalities, genetic anomalies, and environmental factors
[2, 3]. Sawczenko and Sandhu [4] reported that while
abdominal pain, diarrhea, and bloody stool have been
demonstrated as symptoms of IBD, child IBD diﬀers from
adult IBD in that it is associated with short stature due to
growth retardation. With children, prior to the development
of typical symptoms manifesting in the form of diarrhea and
bloody stool, an insuﬃcient increase in body weight is often
found and growth retardation can be observed when growth
is plotted on a chart. Motil et al. [5] reported that growth
retardation occurs more in children with CD than in those
with UC.
Themechanismsunderlyinginsuﬃcientincreaseinbody
weight and growth retardation are reportedly attributed
to a reduction in energy intake, incomplete gastrointesti-
nal tract absorption, an increase in energy requirements,
growth regulation by inﬂammatory cytokines, and long-
term use of therapeutic steroids [6–11]. Particularly in
cases involving children that are diﬃcult to treat, growth
retardation associated with long-term administration of
steroids is a major problem [8]. There are reports such as
suppression of chondrocyte proliferation in the growth plate
and suppression of proteoglycan composition as growth-
inhibiting mechanisms of steroids, because proliferation of
growth plate chondrocytes results in the bone growth [12,
13]. However, details of these mechanisms remain unclear.
At present, there is no long-term observational study
monitoring growth in Japanese children with IBD prior to
treatment and subsequent to steroid therapy. We therefore
investigated the growth retardation in Japanese children
with CD and UC and explored the mechanism underlying
such growth retardation, including malnutrition, chronic
inﬂammation, and steroid administration.
2. Methods
2.1. Subjects. We performed this study in compliance with
the Helsinki Declaration of the World Medical Association.2 International Journal of Pediatrics
−6
−4
−2
H
e
i
g
h
t
v
e
l
o
c
i
t
y
S
D
S
0
2
4
6
P<. 05
CD
Before After
6
(a)
−6
−4
−2
H
e
i
g
h
t
v
e
l
o
c
i
t
y
S
D
S
0
2
4
6
P<. 05
UC
Before After
6
(b)
Figure 1: Comparison of growth rate SDS between children with CD and those with UC during the 1-year period before the initial
assessment and the 1-year period subsequent to the initial assessment. before: 1 year to initial visit; after: from initial visit to 1 year later.
Additionally,thestudywasapprovedbytheClinicalResearch
Ethics Committee of the Juntendo University Hospital and
written parental consent was obtained before inclusion.
We obtained informed consent and enrolled 15 children
diagnosed with CD (male/female: 11/4) and 18 children
diagnosedwithUC(male/female:8/10)amongchildrenwith
ages ranging from 9 months to 15 years and 8 months who
were our patients at the Department of Pediatrics, Juntendo
University School of Medicine or aﬃliated facilities, and
whom we were able to observe continuously from the start
of treatment up to their follow-up examinations (Table 1).
2.2. Procedures. We collected data of the children from their
records which included height and weight at 12 months
and 6 months before the initial IBD diagnosis, at the initial
assessment, and at 6 and 12 months following the start of
treatment subsequent to the initial assessment. From the
collected data, a growth chart was generated using HONE-
TARO ver.5 software (TGL Co., Osaka, Japan). From the
obtained data, height curve SDS and % standard weight were
calculated. Growth rate that was shown as a change in height
SDS during 1 year was also determined using POCKET
GROWTH CHECKER III ver. 1.0 (Ultmarc Co., Tokyo,
Japan). IGF-I, IL-6, TNF-α,a n dT G F - β were measured by
enzyme-linked immunosorbent assay (ELISA) using com-
mercially available assay kits (Fujirebio, Tokyo, Japan). The
CD remission period was deﬁned as having a CD Activity
Index (CDAI) assessed by International Organization for the
Study of IBD [14] of 0 or 1, CRP-negative, and normal
erythrocyte sedimentation. The UC remission period was
deﬁned as the absence of fever, abdominal pain, and bloody
stool, with the stool frequency and fecal characteristics
returning to pre-IBD conditions, testing negative for CRP
and with normal erythrocyte sedimentation. Severity of
children with CD and UC was assessed by the method of
Turner et al. [15] and Truelove and Witts [16], respectively.
We used the Wilcoxon t-test, Mann-Whitney U-test, and
Spearman rank analysis for statistical analysis.
3. Results
There was no signiﬁcant diﬀerence in age at the initial visit
between children with UC and those with CD; however,
children with CD showed a signiﬁcant longer period from
the onset to the initial visit than those with UC (P<. 05).
There was a signiﬁcant increase in the growth rate SDS
in children with CD (P<. 05) but a signiﬁcant decrease in
children with UC (P<. 05) when we compared the growth
rate during the 1-year period before the start of treatment
with the growth rate during the 1-year period subsequent
to treatment (Figure 1). Compared with the 1-year period
before the start of treatment, height SDS in children with
CD at diagnosis was signiﬁcantly lower (P<. 05); however,
there was no signiﬁcant diﬀerence between the pretreatment
level and the level 1 year subsequent to the start of treatment.
On the other hand, in children with UC, there was no
signiﬁcant diﬀerence in height SDS when comparisons were
made between values obtained 1 year before the start of
treatment, at diagnosis, and 1 year subsequent to the start
of treatment (Figure 2).International Journal of Pediatrics 3
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Figure 2: Changes in height SDS in children with CD and those with UC.
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Figure 3: Changes in % standard weight in children with CD and those with UC.4 International Journal of Pediatrics
Table 1: Proﬁle of children with CD (n = 15) and those with UC (n = 18) (mean ± SD).
CD UC
n(M/F) 15(11/4) 18(8/10) N.S.
Average age at the initial visit (year) 9.8 ±5.11 0 .9 ±4.0N . S .
Period of time until the initial visit (week) 28.3 ±27.41 0 .2 ±9.7 P<. 05
Type I 1 case R 3 cases
IC 7 cases L 5 cases
C 7 cases T 10 cases
Severity Mean PCDAI Mild 3 cases
36.2 ±20.0M o d e r a t e 9 c a s e s
Severe 6 cases
Type I: small intestine; Type IC: small intestine/Colon; Type C: colon.
Type R: rectum; Type L: left colon; Type T: total colon.
PCDAI: Pediatric Crohn’s Disease Activity Index [13].
UC severity [14].
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Figure 4: Correlation between growth rate SDS and the amount of PSL administered in children with CD and those with UC from the start
of treatment to 1 year posttreatment.
Compared with the 1-year period before the start of
treatment, % standard weight in the children with CD at
diagnosis was signiﬁcantly lower (P<. 01) but showed
a signiﬁcant increase 1 year subsequent to the start of
treatment (P<. 01). On the other hand, there was no
signiﬁcant diﬀerence between the pretreatment and post-
treatment levels. In subjects with UC, compared with the
1-year period before starting treatment, % standard weight
at diagnosis was found to be signiﬁcantly lower (P<. 05),
and although posttreatment levels tended to be elevated, we
found no signiﬁcant diﬀerence between the pretreatment
and posttreatment levels (Figure 3).
We also compared serum levels of albumin, IGF-1, CRP,
IL-6,TNF-α,andT GF -β,parametersassociatedwithgrowth,
in subjects with CD and those with UC at the initial
assessment and 1 year after the start of treatment. Although
we found that the CRP level was signiﬁcantly (P<. 05)
elevated in subjects with CD compared with those with UC
at the initial assessment, there were no signiﬁcant diﬀerences
between any of the other parameters (Table 2). On the otherInternational Journal of Pediatrics 5
Table 2: Comparison of various parameters at initial assessment and 1 year after the start of treatment in children with CD and those with
UC (mean ± SD).
Admission 1 year after
CD UC CD UC
Alb (g/dL) 3.51 ±0.57 3.67 ±0.65 N.S. 4.36 ±0.33 4.24 ±0.39 N.S.
IGF-I (ng/mL) 270.9 ±219.6 231.8 ±166.1 N.S. 356.7 ±164.7 350.2 ±164.3N . S .
CRP (mg/dL) 3.16 ±3.20 1.35 ±2.59 P<. 05 0.17 ±0.29 0.10 ±0.11 N.S.
IL-6 (pg/mL) 9.74 ±8.34 11.24 ±23.69 N.S. 2.93 ±2.20 2.28 ±3.73 N.S.
TNF-α (pg/mL) 0.76 ±1.17 0.98 ±2.19 N.S. 0.66 ±0.96 1.02 ±1.25 N.S.
TGF-β (ng/mL) 52.71 ±7.36 47.51 ±14.10 N.S. 47.80 ±5.13 44.68 ±12.89 N.S.
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Figure 5: Correlation between serum IGF-I level and the amount
of PSL administered in children with IBD in the 1-year period
following the start of treatment.
hand, we found no signiﬁcant diﬀerences in any of these
parameters between subjects with CD and those with UC 1
year after starting treatment.
Furthermore, we compared the amount of prednisolone
(PSL) used (per kg body weight) and the length of remission
both6monthsand1yearafterthestartoftreatmentbetween
children with CD and those with UC; however, there were no
signiﬁcant diﬀerences (Table 3).
We found a signiﬁcant negative correlation in both
groups (CD group, P<. 01; UC group, P<. 05) when we
compared the correlation between the amount of PSL used
and growth rate 1 year after the start of treatment (Figure 4).
We also found a negative correlation between the amount of
PSL used and IGF-1 level in children with IBD (Figure 5).
4. Discussion
ThepresentresultsindicatethatchildrendiagnosedwithIBD
suﬀered from a signiﬁcant decrease in body weight, both in
children with CD and UC at the start of treatment compared
with their weight 1 year before the start of treatment.
Although there was a signiﬁcant decrease in height in the
children with CD at the start of treatment compared with
their height 1 year earlier, there was no corresponding
decrease among the children with UC. Moreover, a compar-
ison of growth rate 1 year earlier and 1 year after starting
treatment showed a signiﬁcant increase in children with CD,
but a signiﬁcant decrease in those with UC. These results
are consistent with previous results showing that in children
with IBD, growth is impaired in those with CD compared
with those with UC. Langholz et al. [17]r e p o r t e dg r o w t h
r e t a r d a t i o ni ns o m es u b j e c t si nc h i l d r e nw i t hC Dc o m p a r e d
with children with UC. Prieto et al. [18] reported that in
28 children with IBD, growth retardation occurred with
high frequency in children with CD compared with children
with UC. Treatment, including the use of corticosteroid, is
thought to improve this growth impairment. In our study,
actual growth retardation at the time of diagnosis, height
<−2.0 SDS was detected 20% of CD patients and 10% of UC
patients. On the other hand, Hildebrand et al. [19]r e p o r t e d
that height <−2.0 SDS was detected 13% of CD patients and
3% of UC patients. These ﬁndings suggest that both CD and
UCchildreninJapanshowmorefrequentgrowthretardation
than those in Sweden.
In order to determine the cause of the diﬀerence in
growth impairment between children with CD and those
with UC, particularly in terms of increases in height, we
compared nutritional parameters, such as albumin and IGF-
I, cytokines and inﬂammatory markers, including CRP, IL-6,
and TNF-α between children with CD and those with UC.
T h e s ef a c t o r sa r ec o n s i d e r e dt ob er e l a t e dt og r o w t hb e f o r e
treatment. We found that only the CRP level in the children
with CD was signiﬁcantly increased. In several previous
reports, the CRP level has been shown to correlate with the
severityofCD,andhasalsobeenreportedtobeanimportant
indicator of growth retardation [20–24]. Since there was
no signiﬁcant diﬀerence in the levels of albumin and IGF-
I before the start of treatment in either group, as well as
in body weight in both groups, growth impairment before
the start of treatment might not be caused by nutritional
problems. On the other hand, serum CRP level before
treatment was found to be signiﬁcantly elevated in children
with CD, although there were no signiﬁcant diﬀerences
in the levels of IL-6 and TNFα, indicating that growth
impairment before the start of treatment in children with
CD might be aﬀected by chronic inﬂammation. Although
not indicated in the obtained data, there was no signiﬁcant
diﬀerence in growth rate between children with CD having
small intestinal lesions and those having no lesions. These6 International Journal of Pediatrics
Table 3: Comparison of total dose of PSL and remission rates between children with CD and those with UC 6 months and 1 year after the
start of treatment (mean ± SD).
6 months after 1 year after
CD UC CD UC
Total dosage of prednisolone (mg/kg) 116.4 ±132.5 207.8 ±220.6 N.S. 180.4 ±186.5 273.5 ±282.9N . S .
Remission rate (%) 54.08 ±25.92 52.76 ±28.48 N.S. 61.83 ±30.60 65.94 ±19.35 N.S.
results also suggest that nutritional impairment is not the
primary cause of growth impairment in children with
CD. Inﬂammatory markers, including CRP and IL-6, have
a correlation to the disease activity. These markers were
signiﬁcantly increased on admission compared to 1 year
after. There is, however, no signiﬁcant correlation between
levels of CRP and IL-6 and disease activity.
The amount of steroid used is an extremely important
factor aﬀecting post-treatment growth [25]. In the present
study, there was no signiﬁcant diﬀerence in the amount of
PSL used and the remission period between children with
CD and those with UC following the start of treatment at
6 months and 1 year. On the other hand, growth rate and
the amount of PSL used showed a negative correlation in
children with CD and UC, which may indicate that PSL
contributes to growth impairment in IBD children. The
reason for the signiﬁcant diﬀerence in growth impairment
between children with CD and those with UC after the
treatment is that while growth impairment due to chronic
inﬂammation in children with CD occurs prior to treatment,
this condition is reversed by anti-inﬂammatory treatment
following the start of PSL therapy. The decreased growth rate
in children with UC might be due to the side eﬀect of PSL,
because growth rate of children with UC was decreased after
the start of PSL treatment.
Some reports suggest that the mechanism underlying the
growth impairment induced by corticosteroid is an IGF-
I-mediated mechanism acting on the chondrocytes of the
growth plate in a manner that reduces skeletal metabolism
[12,26].Apreviousreportwhichinvestigatedtheassociation
between the administration of exogenous steroids and IGF-1
hasdemonstratedthatthesesteroidscauseimpairmentofthe
IGF axis and a decrease in the level of IGF-binding protein
[27]. Although we conducted the present study without
considering pubertal age, the negative correlation of IGF-1
level and the amount of steroid used in children with IBD
ledustoconsiderthatonemechanismunderlyingthegrowth
impairment induced by corticosteroid in children with IBD
is mediated by the decreased serum level of IGF-I. Although,
there was no signiﬁcant correlation between pretreatment
IGF-I level and growth rate in our study, a previous study
showed that inﬂammatory cytokines induced a decrease in
IGF-I level [28]. Recent study by MacRae et al. [29] indicated
that dexamethasone and IL-1βmight primarily inhibit IGF-
1-induced bone growth. Further investigation should be per-
formed to clarify the relationship among IGF-I, cytokines,
and corticosteroids in growth disturbance of children with
IBD. Moreover we should evaluate their pubertal stage that
is known to be of importance in growth velocity to carefully
investigate growth disturbance in children with IBD.
In conclusion, we investigated growth impairment in
Japanese children with IBD. Chronic inﬂammation was
considered to be responsible for growth impairment in
children with CD before the start of treatment; however,
subsequent to treatment, the primary cause was believed to
depend on the amount of corticosteroid used in children
with IBD. On the other hand, the anti-inﬂammatory eﬀects
of corticosteroids might be necessary to suppress growth
retardation in children with CD.
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